TopoTarget - Scientific Publications

Scientific PublicationsPrimary PublicationsWarren KE, McCully C, Dvinge H, Tjørnelund J, Sehested M, Lichenstein HS, Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates. Cancer Chemother Pharmacol. 2008 Aug;62(3):433-7. Epub 2007 Oct 25. PMID: 17960383 [PubMed - in process]Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology. 2008 Jul 29. [Epub ahead of print] PMID: 18671804 [PubMed - as supplied by publisher]Andrianov V, Gailite V, Lola D, Loza E, Semenikhina V, Kalvinsh I, Finn P, Petersen KD, Ritchie JW, Khan N, Tumber A, Collins LS, Vadlamudi SM, Björkling F, Sehested M. Novel amide derivatives as inhibitors of histone deacetylase: Design, synthesis and SAR. Eur J Med Chem. 2008 Jun 27. [Epub ahead of print] PMID: 18672316 [PubMed - as supplied by publisher]Gimsing P, Hansen M, Knudsen LM, Knoblauch P, Christensen IJ, Ooi CE, Buhl Jensen P. A phase I clinical trial of the histone deacetylase inhibitor belinostat (PXD101) in patients with advanced haematological neoplasia. Eur J Haematol. 2008 May 28. [Epub ahead of print] PMID: 18510700 [PubMed - as supplied by publisher]Marquard L, Petersen KD, Persson M, Hoff KD, Jensen PB, Sehested M. Monitoring the effect of belinostat in solid tumors by H4 acetylation. APMIS. 2008 May;116(5):382-92. PMID: 18452428 [PubMed - indexed for MEDLINE]Dejligbjerg M, Grauslund M, Christensen IJ, Tjørnelund J, Buhl Jensen P, Sehested M. Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines. Cancer Biomark. 2008;4(2):101-9. PMID: 18503161 [PubMed - indexed for MEDLINE]Olesen UH, Christensen MK, Björkling F, Jäättelä M, Jensen PB, Sehested M, Nielsen SJ. Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun. 2008 Mar 21;367(4):799-804. Epub 2008 Jan 15. PMID: 18201551 [PubMed - indexed for MEDLINE]Int J Cancer. 2008 Mar 15;122(6):1400-10 Qian X, Ara G, Mills E, LaRochelle WJ, Lichenstein HS, Jeffers M. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancerQian X, Ara G, Mills E, LaRochelle WJ, Lichenstein HS, Jeffers M. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int J Cancer. 2008 Mar 15;122(6):1400-10. PMID: 18027850 [PubMed - indexed for MEDLINE]Holen K, Saltz LB, Hollywood E, Burk K, Hanauske AR. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs. 2008 Feb;26(1):45-51. Epub 2007 Oct 9. PMID: 17924057 [PubMed - indexed for MEDLINE]Steele NL, Plumb JA, Vidal L, Tjørnelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl Jensen P, Brown R, Evans TR, DeBono JS. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res. 2008 Feb 1;14(3):804-10. PMID: 18245542 [PubMed - indexed for MEDLINE]Clin Cancer Res. 2008 Feb 1;14(3)804-10 Steele NL, Plumb JA, Vidal L, Tjørnelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl Jensen P, Brown R, Evans TR, Debono JS A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumorsClin Cancer Res. 2008 Jan 15;14(2):549-58 Dai Y, Chen S, Kramer LB, Funk VL, Dent P, Grant S. Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia CellsBiochem J. 2008 Jan 15;409(2):581-9 Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitorsKhan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008 Jan 15;409(2):581-9. PMID: 17868033 [PubMed - indexed for MEDLINE]Int J Oncol. 2007 Dec;31(6):1529-38 Stapnes C, Ryningen A, Hatfield K, Øyan AM, Eide GE, Corbascio M, Kalland KH, Gjertsen BT, Bruserud Ø Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitorsBr J Haematol. 2007 Nov;139(3):385-97 Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damageCancer Chemother Pharmacol. 2007 Oct 25 Warren KE, McCully C, Dvinge H, Tjørnelund J, Sehested M, Lichenstein HS, Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primatesJ Transl Med. 2007 Oct 12;5:49 Buckley MT, Yoon J, Yee H, Chiriboga L, Liebes L, Ara G, Qian X, Bajorin DF, Sun TT, Wu XR, Osman I The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivoEtter AL, Bassi I, Germain S, Delaloye JF, Tschopp J, Sordat B, Dupuis M. The combination of chemotherapy and intraperitoneal MegaFas Ligand improves treatment of ovarian carcinoma. Gynecol Oncol. 2007 Oct;107(1):14-21. Epub 2007 Jun 29. PMID: 17604087 [PubMed - indexed for MEDLINE]Grauslund M, Thougaard AV, Füchtbauer A, Hofland KF, Hjorth PH, Jensen PB, Sehested M, Füchtbauer EM, Jensen LH. A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIalpha in vivo. Mol Pharmacol. 2007 Oct;72(4):1003-14. Epub 2007 Jul 10. PMID: 17622580 [PubMed - indexed for MEDLINE]Cancer Chemother Pharmacol. 2007 Jul;60(2):275-83 Anthony Tumber, Laura S. Collins, Kamille Dumong Petersen,·Annemette Thougaard, Sanne J. Christiansen · Marielle Dejligbjerg ·Peter Buhl Jensen · Maxwell Sehested, James W. A. Ritchie The histone deacetylase inhibitor PXD101 synergises with 5-Xuorouracil to inhibit colon cancer cell growth in vitro and in vivoLanger SW, Jensen PB, Sehested M. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries. Cardiovasc Toxicol. 2007;7(2):151-3. Review. PMID: 17652821 [PubMed - indexed for MEDLINE] Mouridsen HT, Langer SW, Buter J, Eidtmann H, Rosti G, de Wit M, Knoblauch P, Rasmussen A, Dahlstrøm K, Jensen PB, Giaccone G. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol. 2007 Mar;18(3):546-50. Epub 2006 Dec 21. PMID: 17185744 [PubMed - indexed for MEDLINE]Buckley MT, Yoon J, Yee H, Chiriboga L, Liebes L, Ara G, Qian X, Bajorin DF, Sun TT, Wu XR, Osman I. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J Transl Med. 2007 Oct 12;5:49. PMID: 17935615 [PubMed - in process]Langer SW. Dexrazoxane for anthracycline extravasation. Expert Rev Anticancer Ther. 2007 Aug;7(8):1081-8. Review. PMID: 18028016 [PubMed - indexed for MEDLINE]J Biol Chem. 2007 Jun 8;282(23):17123-31 Huh YH, Ryu JH, Chun JS. Regulation of type II collagen expression by histone deacetylase in articular chondrocytesTher Drug Monit. 2007 Apr;29(2):231-5 Zhang N, Goh BC, Khoo YM, Yeo W, Lee HS A simple and sensitive high-performance liquid chromatographic method for quantification of PXD101, a histone deacetylase inhibitor in human plasmaMol Cancer Ther. 2007 Jan;6(1)37-50 Jianming Duan, Jay Friedman, Liesl Nottingham, Zhong Chen,1 Gulshan Ara, and Carter Van Waes Nuclear factor-KB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2007 Jan;6(1):37-50. PMID: 17237265 [PubMed - indexed for MEDLINE]Tumber A, Collins LS, Petersen KD, Thougaard A, Christiansen SJ, Dejligbjerg M, Jensen PB, Sehested M, Ritchie JW. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol. 2006 Nov 24; [Epub ahead of print]Pogrebniak A, Schemainda I, Azzam K, Pelka-Fleischer R, Nüssler V, Hasmann M. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Eur J Med Res. 2006 Aug 30;11(8):313-21. PMID: 17052966 [PubMed - indexed for MEDLINE]Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS, Jeffers M.
Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther. 2006 Aug;5(8):2086-95. Jensen LH, Liang H, Shoemaker R, Grauslund M, Sehested M, Hasinoff BB.
A Three-Dimensional Quantitative Structure-Activity Relationship Study of the Inhibition of the ATPase Activity and the Strand Passing Catalytic Activity of Topoisomerase II{alpha} by Substituted Purine Analogs.
Mol Pharmacol. 2006 Nov;70(5):1503-1513. Epub 2006 Jul 31. Beck HC, Nielsen EC, Matthiesen R, Jensen LH, Sehested M, Finn P, Grauslund M, Hansen AM, Jensen ON. Quantitative Proteomic Analysis of Post-translational Modifications of Human Histones.
Mol Cell Proteomics. 2006 Jul;5(7):1314-25. Epub 2006 Apr 20.Greaney P, Nahimana A, Lagopoulos L, Etter AL, Aubry D, Attinger A, Beltraminelli N, Huni B, Bassi I, Sordat B, Demotz S, Dupuis M, Duchosal MA. A Fas agonist induces high levels of apoptosis in haematological malignancies. Leuk Res. 2006 Apr;30(4):415-26. Epub 2005 Sep 21. PMID: 16181674 [PubMed - indexed for MEDLINE]Langer SW, Thougaard AV, Sehested M, Jensen PB. Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. Cancer Chemother Pharmacol. 2006 Jan;57(1):125-8. Epub 2005 Nov 5. PMID: 16001176 [PubMed - indexed for MEDLINE]von Minckwitz G, Harder S, Hövelmann S, Jäger E, Al-Batran SE, Loibl S, Atmaca A, Cimpoiasu C, Neumann A, Abera A, Knuth A, Kaufmann M, Jäger D, Maurer AB, Wels WS. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res. 2005;7(5):R617-26. Epub 2005 Jun 1. Erratum in: Breast Cancer Res. 2006;8(1):403. PMID: 16168106 [PubMed - indexed for MEDLINE]Hofland KF, Thougaard AV, Dejligbjerg M, Jensen LH, Kristjansen PEG, Rengtved P, Sehested M, Jensen PB. Combining Etoposide and Dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors. Clin Cancer Res 2005 11: 6722-6729.Jensen LH, Thougaard AV, Grauslund M, Sokilde B, Carstensen EV, Dvinge HK, Scudiero DA, Jensen PB, Shoemaker RH, Sehested M. Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors. Cancer Res. 2005 Aug 15;65(16):7470-7. Sorensen TK, Grauslund M, Jensen PB, Sehested M, Jensen LH. Separation of bisdioxopiperazine- and vanadate resistance in topoisomerase II. Biochem Biophys Res Commun. 2005 Sep 2;334(3):853-860.Hofland KF, Thougaard AV, Sehested M, Jensen PB. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. Clin Cancer Res. 2005 May 15;11(10):3915-24. Vaughn J, Huang S, Wessel I, Sorensen TK, Hsieh T, Jensen LH, Jensen PB, Sehested M, Nitiss JL. Stability of the topoisomerase II closed clamp conformation may influence DNA stimulated ATP hydrolysis. J Biol Chem. 2005; 280: 11920-11929.La Thangue NB. A mis-matched role for Bcl2. Nature Cell Biology 2005; 7:101-102.Smith L, La Thangue NB. Signalling DNA damage by regulating p53 co-factor activity. Cell Cycle 2005; 4:E152-E154.Helvita Chemica Acta 2005 88(7); 1630-57 Paul W. Finn, Morwena Bandara, Chris Butcher, Angela Finn, Ruth Hollinshead, Nagma Khan, Norman Law, Sreenivasa Murthy, Rosario Romero, Clare Watkins, Victor Andrianov, Rasma M. Bokaldere, Klara Dikovska, Vija Gailite, Einars Loza, Irina Piskunova, Igor Starchenkov, Maxim Vorona, Ivars Kalvinsh Novel Sulfonamide Derivatives as Inhibitors of Histone DeacetylaseDemonacos C, Krstic-Demonacos M., Smith L, Xu, D, O'Connor P, Jansson M, La Thangue, NB. A new effector pathway links ATM kinase with the DNA damage response. Nature Cell Biology 2004; 6:968-976. Logan N, Delavaine L, Reilly C, Wilson J, Brummelkamp TR, Hijmans EM, Bernards R, La Thangue NB. E2F-7: a distinctive E2F family member with an unusual organization of DNA binding domains. Oncogene 2004; 23:5138-5150.Plumb JA, Steele N, Finn PW, Brown R. Epigenetic approaches to Cancer Therapy. Biochemical Society Transactions 2004; 32:1095-1097.Walker JV, Nitiss KC, Jensen LH, Mayne C, Hu T, Jensen PB, Sehested M, Hsieh T, Nitiss JL. A mutation in human topoisomerase II alpha whose expression is lethal in DNA repair-deficient yeast cells. Biol. Chem. 2004; 279:25947-25954.McLaughlin F, La Thangue NB. Histone deacetylase inhibitors open new doors in cancer. Biochemical Pharmacology 2004; 68:1139-1144.Kerr DJ, La Thangue NB. Signal transduction blockade and cancer: combination therapy or multi-targeted inhibitors? Annals of Oncology 2004; 15:1727-1729.La Thangue NB. Histone deacetylase inhibitors and cancer therapy. J. Chemotherapy 2004; 16:64-67.Stevens C, La Thangue NB. The emerging role of E2F-1 in the DNA damage response and checkpoint control. DNA Repair 2004; 3:1071-1079.Azemar M, Djahansouzi S, Jäger E, Solbach C, Schmidt M, Maurer AB, Mross K, Unger C, von Minckwitz G, Dall P, Groner B, Wels WS. Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res Treat. 2003 Dec;82(3):155-64. PMID: 14703062 [PubMed - indexed for MEDLINE]Schroeder PE, Hofland KF, Jensen PB, Sehested M, Langer SW, Hasinoff BB. Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent. Cancer Chemother Pharmacol. 2004 Jan;53(1):91-3. Epub 2003 Oct 22. PMID: 14574459 [PubMed - indexed for MEDLINE]Drevs J, Löser R, Rattel B, Esser N. Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Res. 2003 Nov-Dec;23(6C):4853-8. PMID: 14981935 [PubMed - indexed for MEDLINE]Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 2003 Nov 1;63(21):7436-42. PMID: 14612543 [PubMed - indexed for MEDLINE]Jensen JN, Lock-Andersen J, Langer SW, Mejer J. Dexrazoxane-a promising antidote in the treatment of accidental extravasation of anthracyclines. Scand J Plast Reconstr Surg Hand Surg. 2003;37(3):174-5. PMID: 12841619 [PubMed - indexed for MEDLINE]Schroeder PE, Jensen PB, Sehested M, Hofland KF, Langer SW, Hasinoff BB. Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide. Cancer Chemother Pharmacol. 2003 Aug;52(2):167-74. Epub 2003 May 15. PMID: 12750840 [PubMed - indexed for MEDLINE]Cowland J, Soerensen OE, Sehested M, Borregaard N. Neutrophil Gelatinase-Associated Lipocalin (NGAL) is Upregulated in Human Epithelial Cells by IL-1 but not by TNF. J. Immunol. 2003; 171:6630-6639.Jensen LH, Renodon-Cornière A, Nitiss KC, Hill BT, Nitiss JL, Jensen PB, Sehested M. A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase. Biochem. Pharmacol. 2003; 66:623-631.La Cour J, Mollerup J, Winding P, Tarabykina S, Sehested M, Berchtold MW. Up-regulation of ALG-2 in hepatomas and lung cancer tissue. Am J Pathol 2003; 163:81-89.McLaughlin F, Finn PW, LaThangue NB. The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age. Drug Discovery Today 2003; 8:793-802.Plumb JA, Finn PW, Williams RJ, Bandara MW, Romero MR, Watkins CJ, La Thangue NB, Brown R. Pharmacodynamic response and inhibition of growth of human tumour xenografts by the novel histone deacetylase inhibitor PXD101. Mol. Cancer Ther. 2003; 2:721-728.Renodon-Cornière A, Sørensen TK, Jensen PB, Nitiss JL, Søkilde B, Sehested M, Jensen LH. Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild type and mutant human topoisomerase II. Mol. Pharmacol. 2003; 63:1159-1168.Stevens C, Smith L, La Thangue NB. Checkpoint kinase activates E2F-1 in response to DNA damage. Nature Cell Biology 2003; 5:401-409.Demonacos C, La Thangue NB. Drug discovery and the p53 family. Prog. Cell Cycle Res. 2003; 5:375-382.McLaughlin F, Finn PW, La Thangue NB. The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age. Drug Discovery Today 2003; 8:793-802.McLaughlin F, La Thangue NB. Histone deacetylase inhibitors in psoriasis therapy. Inflammation and Allergy 2003; 3: 213-219.La Thangue NB. The yin and yang of E2F-1: balancing life and death. Nature Cell Biology 2003; 5:587-589.La Thangue NB. Theoretical foundations in cancer chemotherapy. Enc. Mol. Cell. Biol. Mol. Med. 2003;171-189.Stevens C, La Thangue NB. A new role for E2F-1 in checkpoint control. Cell Cycle 2003; 2:e1-e3.Stevens C, La Thangue NB. E2F and cell cycle control: a double edged sword. Archives of Biochemistry and Biophysics 2003; 412:157-169.Di Tullio RA, Mochan TA, Venere M, Bartkova J, Sehested M, Bartek J, Halazonetis TD. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nature Cell Biol. 2002; 4:998-1002.Mason S, Loughran Ö, La Thangue NB. p14^ARF regulates E2F activity. Oncogene 2002; 21:4220-4230.Jensen LH, Renodon-Corniere A, Wessel I, Langer SW, Søkilde B, Carstensen EV, Sehested M, Jensen PB. Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo. - A new mode of catalytic inhibition. Molecular Pharmacol 2002; 61:1235-1243.Kellner U, Sehested M, Jensen PB, Gieseler F, Rudolph P. Culprit and victim - DNA topoisomerase II. Lancet Oncology 2002; 3:325-343.Renodon-Corniere A, Jensen LH, Nitiss JL, Jensen PB, Sehested M. Interaction of Human DNA Topoisomerase II alpha with DNA: Quantification by Surface Plasmon Resonance. Biochemistry 2002; 41:13395-13402.Rothenborg-Jensen L, Hansen HF, Wessel I, Nitiss JL, Schmidt G, Jensen PB, Sehested M, Jensen LH. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines. Anti-Cancer Drug Design 2002; 16:305-315.Wessel I, Jensen LH, Renodon-Corniere A, Sorensen TK, Nitiss JL, Jensen PB, Sehested M. Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase ll.. FEBS Letters 2002; 520:161-166.Bandara LR, La Thangue NB. Targets for cancer chemotherapy: Transcription factors and other nuclear proteins. Humana Press Eds. 2002.Loughran Ö, La Thangue NB. E2F: a family of transcription factors implicated in cell cycle control. Current Biology 2002; 12:R377.La Thangue NB. Chromatin control - a place for E2Fand Myc to meet. Science 2002; 296:1034-1035.McLaughlin F, La Thangue NB. Tumour classification for tailored cancer therapy. Annual Reports in Med. Chem. 2002; 37:225-235.Langer SW, Sehested M, Jensen PB. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Ann Oncol. 2001 Mar;12(3):405-10. PMID: 11332155 [PubMed - indexed for MEDLINE]Chan HM, Shikama N, La Thangue NB. "Control of gene expression and the cell cycle." in Essays in Biochemistry - Regulation of Gene Expression 2001;. 37: K. Chapman, ed., Portland Press, pp. 87-96.Bergman AM, Munch-Petersen B, Jensen PB, Sehested M, Veerman G, Voorn DA, Smid K, Pinedo HM, Peters GJ. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines. Biochem. Pharmacol. 2001; 61:1401-1408. Chan HM, Krstic-Demonacos M, Smith L, Demonacos C, La Thangue NB. Acetylation control of the retinoblastoma tumour suppressor protein. Nature Cell Biol. 2001; 3:667-674.Chan HM, Smith L, La Thangue NB. Role of LXCXE motif-dependent interactions in the activity of the retinoblastoma protein. Oncogene 2001; 20:6152-6163.Demonacos C, Krstic-Demonacos M, La Thangue NB. A novel TPR-motif co-factor contributes to p300 activity in the p53 response. Mol. Cell. 2001; 8:71-84.Lukas C, Bartkova J, Latella L, Falck J, Mailand N, Schroeder T, Sehested M, Lukas J, Bartek J. DNA damage-activated kinase Chk2 is independent of proliferation or differentiation yet correlates with tissue biology. Cancer Res. 2001; 61:4990-4993.Nielsen BS, Sehested M, Duun S, Rank F, Timshel S, Rygard J, Johnsen M, Danø K. Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. Lab. Invest. 2001; 81:1485-501.Chan H-M, La Thangue NB. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J. Cell Science. 2001; 114:2363-2373.Langer SW, Sehested M, Jensen PB. Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res. 2000 Sep;6(9):3680-6. PMID: 10999761 [PubMed - indexed for MEDLINE]Langer SW, Sehested M, Jensen PB, Buter J, Giaccone G. Dexrazoxane in anthracycline extravasation. J Clin Oncol. 2000 Aug;18(16):3064. No abstract available. PMID: 10944144 [PubMed - indexed for MEDLINE]Clark W, Black EJ, MacLaren A, Kruse U, La Thangue NB, Vogt PK, Gillespie DAF. v-Jun overrides the mitogen dependence of S-phase entry by deregulating retinoblastoma protein phosphorylation and E2F-pocket protein interactions as a consequence of enhanced cyclinE-cdk2 catalytic activity. Mol. Cell. Biol. 2000; 20:2529-2542. Hofland K, Petersen BO, Falck J, Helin K, Jensen PB, Sehested M. Differential cytotoxic pathways of topoisomerase I and II anticancer agents following overexpression of the E2F-1/DP-1 transcription factor complex. Clin. Cancer Res. 2000; 6:1488-1497.Jensen LH, Nitiss KC, Rose A, Dong J, Zhou J, Hu T, Osheroff N, Jensen PB, Sehested M, Nitiss J. A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines. J. Biol. Chem. 2000; 275:2137-2146.Jensen LH, Wessel I, Møller M, Nitiss JL, Sehested M, Jensen PB. N-terminal and core-domain random mutations in human topoisomerase II conferring bisdioxopiperazine resistance. Febs Lett. 2000; 480:201-207.La Valle SM, Finn PW, Kavraki LE, Latombe J-C. A Randomized Kinematics-Based Approach to Pharmacophore-Constrained Conformational Search and Database Screening. Journal of Computational Chemisty 2000; 21:731-747.Morris L, Allen KE, La Thangue NB. Regulation of E2F transcription by cyclinE/cdk2 kinase mediated through p300/CBP co-activators. Nature Cell Biology 2000; 2:232-239.Loughran Ö, La Thangue NB. Apoptotic and growth-promoting activity of E2F modulated by MDM2. Molecular and Cellular Biology 2000; 20:2186-2197.Shikama N, Chan H-M, Smith L, Krstic-Demonacos M, Lee C-W, Cairns W, La Thangue NB. Functional interaction between nucleosome assembly proteins and p300/CBP co-activators. Molecular and Cellular Biology 2000; 20:8933-8943.Chan H-M, La Thangue NB. Regulation of the retinoblastoma protein. Cancer Encyclopædia 2000, Springer Verlag.Langer SW, Schmidt G, Sørensen M, Sehested M, Jensen PB. Inhibitors of topoisomerase II as pH-dependent modulators of etoposide-mediated cytotoxicity. Clin Cancer Res. 1999 Oct;5(10):2899-907. PMID: 10537359 [PubMed - indexed for MEDLINE]Delavaine L, La Thangue NB. Control of E2F activity by p21Waf1/Cip1. Oncogene 1999; 18:5381-5392.Brooks G, La Thangue NB. Drug discovery and the cell cycle: The promise and the hope. Drug Discovery Today 1999; 4:455-464. De la Luna S, Allen KE, Mason SL, La Thangue NB. Integration of a growth-suppressing BTB/POZ domain protein with the DP component of the E2F transcription factor. EMBO Journal 1999; 18:212-228.Lee C-W, La Thangue NB. Promoter specificity and stability control of the p53-related protein p73. Oncogene 1999; 18:4171-4181.Shikama N, Lee C-W, Delavaine S, France J, Lyon W, Krstic-Demonacos M, La Thangue NB. A novel co-factor for p300 that regulates the p53 response. Molecular Cell 1999; 4:365-376.